A patient diagnosed with Parkinson disease (PD) has been prescribed benztropine (Cogentin). What information will the healthcare provider prescribing the medication share with the patient?

A. "This medication may help your narrow-angle glaucoma.": Benztropine is contraindicated in narrow-angle glaucoma because its anticholinergic effects can increase intraocular pressure and worsen the condition. Patients with glaucoma should avoid this medication. B. "You may experience mild improvement in both your short- and long-term memory.": Benztropine does not enhance memory; it primarily reduces tremor and rigidity in Parkinson’s disease by restoring the balance between acetylcholine and dopamine in the CNS. Cognitive improvement is not an expected effect. C. "The medication may trigger temporary drooling.": Benztropine often reduces drooling because it decreases salivary secretions. An increase in drooling is not typical; patients may instead experience dry mouth as a side effect. D. "You will feel the effects of the medication in about one hour.": Oral benztropine is rapidly absorbed, and patients generally notice improvement in tremor and rigidity within about one hour of administration. This information sets realistic expectations for therapeutic onset.